OM:CAMX
OM:CAMXPharmaceuticals

How FDA Review of Oclaiz Could Shape Camurus’ (OM:CAMX) Long-Term Endocrinology Strategy

Camurus AB (publ) recently announced that the U.S. FDA has accepted for review its resubmitted New Drug Application for Oclaiz (CAM2029), an extended-release octreotide injection for acromegaly, with a PDUFA target action date set for 10 June 2026. This acceptance helps clear a prior hurdle tied to third-party manufacturing observations and follows earlier EU and UK approvals and launch of the same product, marketed there as Oczyesa. We will now examine how FDA acceptance of the Oclaiz...
OM:HANZA
OM:HANZAElectronic

Exploring 3 European Undervalued Small Caps With Insider Action

The European market has shown resilience, with the pan-European STOXX Europe 600 Index ending higher, buoyed by strong economic data and earnings results. As small-cap stocks continue to attract attention in this environment, identifying those with solid fundamentals and insider activity can offer intriguing opportunities for investors seeking potential value.
OM:DYVOX
OM:DYVOXTech

European Stocks Trading At Estimated Discounts

Amidst a mixed performance in major European stock indexes, with the STOXX Europe 600 Index ending slightly higher due to resilient economic data and earnings results, investors are keenly observing opportunities for undervalued stocks. In this environment, identifying stocks trading at estimated discounts can be attractive for those looking to capitalize on market inefficiencies and potential growth prospects.
OM:NOBI
OM:NOBIConsumer Durables

Assessing Nobia (OM:NOBI) Valuation After UK Exit Plan And SEK 1.5b Rights Issue

Why Nobia’s rights issue and UK exit matter for shareholders Nobia (OM:NOBI) is overhauling its business by selling its UK operations, refocusing on Nordic markets, and raising approximately SEK 1.5b through a rights issue, together with new loan agreements and planned capital structure changes. See our latest analysis for Nobia. The rights issue, UK exit and refinancing have come against a weak share price backdrop, with a 7 day share price return of 27.12% decline and a 5 year total...
OM:BONEX
OM:BONEXBiotechs

Assessing Bonesupport Holding’s Valuation After Strong Q4 2025 Update And 2026 Growth Outlook

Bonesupport Holding (OM:BONEX) shares are back in focus after the company issued preliminary fourth quarter 2025 figures, indicating 36% net sales growth to 313 MSEK and providing guidance for sales growth above 35% for 2026. See our latest analysis for Bonesupport Holding. The preliminary Q4 2025 update came after a mixed share price run, with a 7 day share price return of 14.18% and a 30 day gain of 18.21% contrasting with a 90 day share price decline of 17.90% and a 1 year total...
OM:SOBI
OM:SOBIBiotechs

Assessing Swedish Orphan Biovitrum (OM:SOBI) Valuation After Recent Share Price Weakness

Recent share price performance and business profile Swedish Orphan Biovitrum (OM:SOBI) has seen mixed share price moves recently, with a 2.5% decline over the past day and a 4.7% decline over the past week, but a modest gain over the past month. Over longer periods, the stock shows a small 1 year total return near flat. The past 3 years and past 5 years reflect much stronger total returns compared with shorter term performance. The company focuses on haematology, immunology, and specialty...
OM:TRUE B
OM:TRUE BSoftware

A Look At Truecaller (OM:TRUE B) Valuation After Fresh Share Buybacks And AGM Timing

Truecaller (OM:TRUE B) has completed another round of share repurchases, taking treasury holdings to 5.02%, with the buyback programme timed ahead of the company’s 2026 Annual General Meeting. See our latest analysis for Truecaller. Despite the latest buybacks, the share price has come under pressure, with a 1 day share price return of a 2.96% decline, a 7 day share price return of a 9.94% decline and a 90 day share price return of a 57.88% decline. The 1 year total shareholder return of a...
OM:BETS B
OM:BETS BHospitality

Assessing Betsson (OM:BETS B) Valuation After Weaker Q4 2025 Guidance And Share Price Drop

Why Betsson’s latest guidance has grabbed investor attention Betsson (OM:BETS B) has come under pressure after preliminary Q4 2025 guidance pointed to softer results, with revenue expected at €304 million and operating income at €53 million, both below the prior year. The update, combined with weaker sportsbook and B2B trends, triggered a sharp share price reaction. This has left many investors reassessing how the business mix, regional performance, and ongoing product investments could shape...
OM:ERIC B
OM:ERIC BCommunications

A Look At Ericsson’s (OM:ERIC B) Valuation After Announced Staff Reductions In Sweden

Telefonaktiebolaget LM Ericsson (OM:ERIC B) has drawn fresh investor attention after announcing proposed staff reductions affecting about 1,600 positions in Sweden, as part of wider cost focused initiatives across the group. See our latest analysis for Telefonaktiebolaget LM Ericsson. At a share price of SEK 87.52, Ericsson has seen a 1-year total shareholder return decline of 4.82%, although the 3-year total shareholder return of 68.28% suggests longer term momentum has been stronger than...
OM:SKA B
OM:SKA BConstruction

Does Skanska’s SEK 1.30 Billion Stockholm Project Clarify Its Urban Mixed‑Use Strategy (OM:SKA B)?

Skanska recently acquired the Tegelbruket 4 property on central Kungsholmen in Stockholm from Region Stockholm, committing SEK 1.30 billion to develop about 240 tenant-owned apartments, offices, commercial premises and new park space while preserving historic buildings. This mixed-use urban project underlines Skanska’s focus on long-duration, city-center developments that combine residential, office, retail and environmental features within a single neighborhood. We’ll now examine how this...